Colin Glenn Begley
Founder at Incendia Therapeutics, Inc.
Profile
Colin Glenn Begley is the founder of Incendia Therapeutics, Inc. He worked as a Non-Executive Director at Oxford BioTherapeutics Ltd., Director at Cyterix Pharmaceuticals, Inc., and Executive Director at Western Australian Institute For Medical Research.
He was also a VP, Global Head-Hematology & Oncology Research at Amgen, Inc. and Chief Scientific Officer at TetraLogic Pharmaceuticals Corp.
He held the position of Head-Human Leukemia Laboratory at The Walter & Eliza Hall Institute of Medical Research and was a Professor at the University of Melbourne.
Dr. Begley earned two doctorate degrees from the University of Melbourne in 1978 and 1986.
Colin Glenn Begley active positions
| Companies | Position | Start |
|---|---|---|
Incendia Therapeutics, Inc.
 Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Founder | - |
Former positions of Colin Glenn Begley
| Companies | Position | End |
|---|---|---|
| TETRALOGIC PHARMACEUTICALS CORPORATION | Chief Tech/Sci/R&D Officer | 2016-04-18 |
| AMGEN INC. | Corporate Officer/Principal | 2011-12-31 |
Cyterix Pharmaceuticals, Inc.
 Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Director/Board Member | - |
The Walter & Eliza Hall Institute of Medical Research
 The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia. | Corporate Officer/Principal | - |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | - |
Training of Colin Glenn Begley
| University of Melbourne | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 5 |
|---|---|
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
| Western Australian Institute For Medical Research | |
The Walter & Eliza Hall Institute of Medical Research
The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia. | Commercial Services |
Cyterix Pharmaceuticals, Inc.
Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Health Technology |
Incendia Therapeutics, Inc.
Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Health Technology |
- Stock Market
- Insiders
- Colin Glenn Begley
